Printer Friendly

BioInvent International announces receipt of notice of allowance from USPTO relevant to its F.I.R.S.T platform.

Global Banking News-September 27, 2018-BioInvent International announces receipt of notice of allowance from USPTO relevant to its F.I.R.S.T platform

(C)2018 ENPublishing - http://www.enpublishing.co.uk

BioInvent International AB (STO:BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, announced on Wednesday the issuance by the US Patent and Trademark Office (USPTO) of a notice of allowance, informing the company that a patent application relevant to its unique, function-based F.I.R.S.T platform now can proceed to be granted.

Reportedly, this patent application relates to combined use of differential biopanning and next generation sequencing, NGS, in identification of antibodies to differentially expressed cell surface antigens. This patent is expected to be granted once BioInvent has responded to the USPTO's notice.

According to the company, corresponding patents have already been granted by the European Patent Office (EPO) and in Australia, Japan and Russia. The company has similar patent applications pending in further countries.

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:Sep 27, 2018
Words:176
Previous Article:IC Group reports on resolutions at AGM.
Next Article:BJ's Wholesale Club Holdings prices follow-on offering of 28m common stock by selling stockholders at USD26.00 per share.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters